High-grade mature B-cell lymphoma with Burkitt-like morphology: Results of a clinicopathological study of 72 Japanese patients

Cancer Science

Volumn 99, Issue 2, 2008, Pages 246-252

  Nomura, Yuko ^a,b   Karube, Kennosuke ^a   Suzuki, Ritsuro ^c   Ying, Guo ^d   Takeshita, Morishige ^b   Hirose, Shinichi ^b   Nakamura, Nhigeo ^c   Yoshino, Tadashi ^e   Kikuchi, Masahiro ^b   Ohshima, Koichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^e OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; KI 67 ANTIGEN; MYC PROTEIN; PREDNISOLONE; PROTEIN BCL 2; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BONE MARROW METASTASIS; BURKITT LYMPHOMA; CANCER GRADING; CHILD; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; JAPANESE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SHORT COURSE THERAPY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BURKITT LYMPHOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; JAPAN; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 38949176013     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00681.x     Document Type: Article

References (26)

1. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
2. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35.
3. Diebold JE, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe ESHN, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours. Lyon: IARC Press, 2001.
4. Braziel RM, Arber DA, Slovak ML et al. The Burkitt-like lymphomas: A Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood 2001; 97: 3713-20.
5. McClure RF, Remstein ED, Macon WR et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol 2005; 29: 1652-60.
6. Macpherson N, Lesack D, Klasa R et al. Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: Cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999; 17: 1558-67.
7. Yano T, Van Krieken JH, Magrath IT, Longo DL, Jaffe ES, Raffeld M. Histogenetic correlations between subcategories of small noncleaved cell lymphomas. Blood 1992; 79: 1282-90.
8. Nakamura N, Nakamine H, Tamaru J et al. The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Mod Pathol 2002; 15: 771 s -6.
9. Spina D, Leoncini L, Megha T et al. Cellular kinetic and phenotypic heterogeneity in and among Burkitt's and Burkitt-like lymphomas. J Pathol 1997; 182: 145-50.
10. Hummel M, Bentink S, Berger H et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-30.
11. Cairo MS, Sposto R, Perkins SL et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the Children's Cancer Group experience. Br J Haematol 2003; 120: 660-70.
12. Schwenn MR, Blattner SR, Lynch E, Weinstein HJ. HiC-COM: A 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol 1991; 9: 133-8.
13. Kawasaki C, Ohshim K, Suzumiya J et al. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma 2001; 42: 1099-106.
14. Ohshima K, Kawasaki C, Muta H et al. CD10 and bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156-62.
15. Zhang A, Ohshima K, Sato K et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas. Pathol Int 1999; 49: 1043-52.
16. Li JY, Gaillard F, Moreau A et al. Detection of translocation t (11;14)(q13;q32) in mantle cell lymphoma by fluorescence in.situ hybridization. Am J Pathol 1999; 154: 1449-52.
17. Kodama T, Ohshima K, Nomura K et al. Lymphomatous polyposis of the gastrointestinal tract, including mantle cell lymphoma, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma. Histopathology 2005; 47: 467-78.
18. Frost M, Newell J, Lones MA, Tripp SR, Cairo MS, Perkins SL. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol 2004; 121: 384-92.
19. Haralambieva E, Boerma EJ, Van Imhoff GW et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol 2005; 29: 1086-94.
20. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000; 18: 3707-21.
21. Au WY, Horsman DE, Gascoyne RD, Viswanatha DS, Klasa RJ, Connors JM. The spectrum of lymphoma with 8q24 aberrations: A clinical, pathological and cytogenetic study of 87 consecutive cases. Leuk Lymphoma 2004; 45: 519-28.
22. Dave SS, Fu K, Wright GW et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-42.
23. Todeschini G, Tecchio C, Degani D et al. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: No differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 1997; 8 (Suppl 1): 77-81.
24. Adde M, Shad A, Venzon D et al. Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas. Semin Oncol 1998; 25: 33-9.
25. Crom WR, Glynn-Barnhart AM, Rodman JH et al. Pharmacokinetics of anticancer drugs in children. Clin Pharmacokinet 1987; 12: 168-213.
26. Fairbanks LD, Ruckemann K, Qiu Y et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: A metabolic basis for efficacy in rheumatoid arthritis? Biochem J 1999; 342: 143-52.